SCHEMBL21333087

SCHEMBL21333087

NCCc1c[nH]c2c(OP=O)cccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.68
LTA4H P09960 1/20 0.60
PLA2G2A P14555 1/20 0.60
TRPM8 Q7Z2W7 1/20 0.60
MPO P05164 8/20 0.57
SLC6A4 P31645 5/20 0.57
MAPT P10636 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
HTR6 P50406 2/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2A6 P11509 1/20 0.46
NFKB1 P19838 1/20 0.46
HTR1D P28221 1/20 0.46
HTR1B P28222 1/20 0.46
HTR2C P28335 1/20 0.46
HTR7 P34969 1/20 0.46
CTSK P43235 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23211671 0.82 HTR6 (0.71) HTR2ALTA4HPLA2G2ATRPM8MPO
SCHEMBL1424902 0.81 HTR2A (1.00) HTR2ALTA4HPLA2G2ATRPM8MPO
SCHEMBL21333273 0.80 MPO (0.57) HTR2ALTA4HPLA2G2ATRPM8MPO
Hydrochloric Acid SCHEMBL7823519 0.79 HTR2A (0.97) HTR2ALTA4HPLA2G2ATRPM8MPO
SCHEMBL14907351 0.78 HTR2A (0.74) HTR2ALTA4HPLA2G2ATRPM8MPO
SCHEMBL14962766 0.77 HTR2A (0.68) HTR2ALTA4HPLA2G2ATRPM8MPO
SCHEMBL15732779 0.77 HTR2A (0.68) HTR2ATRPM8MPOHTR6CYP1A2
SCHEMBL30579433 0.75 LTA4H (1.00) HTR2ALTA4HPLA2G2ATRPM8MPO
SCHEMBL5167328 0.75 LTA4H (1.00) HTR2ALTA4HPLA2G2ATRPM8MPO
SCHEMBL1460642 0.73 MPO (0.70) HTR2ALTA4HPLA2G2ATRPM8MPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595497-B2 Processes for the production of tryptamines COMPASS PATHFINDER LIMITED (GB) 2026-04-07 US claimed
US-12595497-B2 Processes for the production of tryptamines COMPASS PATHFINDER LIMITED (GB) 2026-04-07 US disclosed
US-20240084344-A1 PROCESSES FOR THE PRODUCTION OF TRYPTAMINES COMPASS PATHFINDER LIMITED (GB) 2024-03-14 US disclosed
US-11661617-B2 Processes for the production of tryptamines COMPASS PATHFINDER LIMITED (GB) 2023-05-30 US disclosed
US-11136293-B2 Processes for the production of tryptamines NEW ATLAS BIOTECHNOLOGIES LLC (US) 2021-10-05 US disclosed
US-20210277433-A1 PROCESSES FOR THE PRODUCTION OF TRYPTAMINES HERCULES CAPITAL, INC. 2021-09-09 US disclosed
US-20210108238-A1 PROCESSES FOR THE PRODUCTION OF TRYPTAMINES HERCULES CAPITAL, INC. 2021-04-15 US disclosed
EP-3762498-A1 PROCESSES FOR THE PRODUCTION OF TRYPTAMINES New Atlas Biotechnologies LLC (US) 2021-01-13 EP disclosed
CN-112105734-A Method for producing tryptamine 新图集生物技术有限责任公司 2020-12-18 CN disclosed
WO-2019173797-A1 PROCESSES FOR THE PRODUCTION OF TRYPTAMINES NEW ATLAS BIOTECHNOLOGIES LLC (US) 2019-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595497-B2 Processes for the production of tryptamines INMT, TPH1, TPH2 HTR2A 67/4885LTA4H 960/4885PLA2G2A 1919/4885
US-11661617-B2 Processes for the production of tryptamines TPH1, TPH2, AANAT HTR2A 38/4885LTA4H 876/4885PLA2G2A 341/4885
US-20240084344-A1 PROCESSES FOR THE PRODUCTION OF TRYPTAMINES TPH1, TPH2, AANAT HTR2A 38/4885LTA4H 876/4885PLA2G2A 341/4885
US-11136293-B2 Processes for the production of tryptamines TPH1, TPH2, AANAT HTR2A 38/4885LTA4H 876/4885PLA2G2A 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.